Reports & eBooks

Drug Pipeline & Clinical Update - August 2023

September 5, 2023

Capital Rx


  • Five key new approvals, including AkeegaTM for prostate cancer, ZurzuvaeTM for postpartum depression, and Xdemvy® for demodex blepharitis
  • One biosimilar approval: Tyruko® for MS (biosimilar to Tysabri®)
  • Two notable expanded indications, two pipeline updates, and seven generic launches
  • Capital Rx's Updated Drug Recall Report: CLICK HERE to review

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our August 2023 Monthly Drug Update!

Key New Drug Approvals

Xdemvy® (lotilaner) ophthalmic solution

Approval Date: 07/25/2023 - CLICK HERE for the press release

Indication: Demodex blepharitis

Cost*: $1,850 per 6-week treatment

Key Considerations:

RiVive™ (naloxone) nasal spray

Approval Date: 07/28/2023 - CLICK HERE for the press release

Indication: Known or suspected opioid overdose emergency

Cost*: TBD

Key Considerations:

Zurzuvae™ (zuranolone) capsule

Approval Date: 08/4/2023 - CLICK HERE for the press release

Indication: Postpartum depression

Cost*: TBD

Key Considerations:

Akeega™ (niraparib and abiraterone acetate) tablet

Approval Date: 08/11/2023 - CLICK HERE for the press release

Indication: BRCA-positive metastatic castration-resistant prostate cancer

Cost*: $625 per tablet

Key Considerations:

Sohonos™ (palovarotene) capsule

Approval Date: 08/16/2023 - CLICK HERE for the press release

Indication: Fibrodysplasia ossificans progressiva

Cost*: $1,710 per capsule

Key Considerations:

Biosimilar Approvals

Tyruko® (natalizumab-sztn) intravenous injection

Approval Date: 08/25/2023 - CLICK HERE for the press release

Indication: Biosimilar to Tysabri® (natalizumab) indicated for the treatment of multiple sclerosis and Crohn’s disease

Additional Information:

Generic Launches

Symbicort® (Breyna, budesonide-formoterol fumarate dihyd 80-4.5 mcg/act, 160-4.5mcg/act) aerosol

Onglyza® (saxagliptin 2.5mg, 5mg) tablet

Kombiglyze XR® (saxagliptin-metformin 2.5-1000mg, 5-500mg, 5-1000mg) extended-release tablet

Spiriva Handihaler® (tiotropium 18mcg) inhaled capsule

Trionex® (calcipotriene 0.005%) cream dressing kit

Balcoltra® (levonorgestrel-ethinyl estradiol-fe 0.1mg-20mcg) tablet

Vyvanse® (lisdexamfetamine 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg) capsules and chewable tablets

Notable Expanded Indications

Lonsurf® (tipiracil/trifluridine)- expanded to be used in combination with bevacizumab indicated for the treatment of metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type

Ingrezza® (valbenazine)-expanded to treat Chorea associated with Huntington's disease

Notable Pipeline Medication Updates

Beyfortus™ (nirsevimab-alip) subcutaneous injection

Approval Date: 07/17/2023 - CLICK HERE for the press release

Indication: Prevention of serious lower respiratory tract disease due to respiratory syncytial virus (RSV)

Cost*: $594 per vial

Key Considerations:

Abrysvo™ (Respiratory Syncytial Virus Vaccine) subcutaneous injection

Approval Date: 08/21/2023 - CLICK HERE for the press release

Indication: Respiratory syncytial virus (RSV)

Cost*: $354 per dose

Key Considerations:

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.


* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights

Sign up for our newsletter!

Get the latest information on JUDI news, webinars, and industry insights through our newsletter. Sign up now!